Genethera Stock Total Debt
| GTHR Stock | USD 0.0001 0.00 0.00% |
GeneThera fundamentals help investors to digest information that contributes to GeneThera's financial success or failures. It also enables traders to predict the movement of GeneThera Pink Sheet. The fundamental analysis module provides a way to measure GeneThera's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GeneThera pink sheet.
GeneThera |
GeneThera Company Total Debt Analysis
GeneThera's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current GeneThera Total Debt | 806.87 K |
Most of GeneThera's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GeneThera is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Based on the latest financial disclosure, GeneThera has a Total Debt of 806.87 K. This is 99.97% lower than that of the Healthcare sector and 99.75% lower than that of the Biotechnology industry. The total debt for all United States stocks is 99.98% higher than that of the company.
GeneThera Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GeneThera's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of GeneThera could also be used in its relative valuation, which is a method of valuing GeneThera by comparing valuation metrics of similar companies.GeneThera is currently under evaluation in total debt category among its peers.
GeneThera Fundamentals
| Return On Asset | -95.38 | |||
| Current Valuation | 1.44 M | |||
| Shares Outstanding | 35.33 M | |||
| Shares Owned By Insiders | 17.99 % | |||
| Price To Earning | (0.17) X | |||
| EBITDA | (1 M) | |||
| Net Income | (1.01 M) | |||
| Cash And Equivalents | 140.1 K | |||
| Total Debt | 806.87 K | |||
| Book Value Per Share | (0.24) X | |||
| Cash Flow From Operations | (8.57 K) | |||
| Earnings Per Share | (0.03) X | |||
| Beta | 0.89 | |||
| Market Capitalization | 533.53 K | |||
| Total Asset | 6.3 K | |||
| Retained Earnings | (25.59 M) | |||
| Working Capital | (7.03 M) | |||
| Current Asset | 55 K | |||
| Current Liabilities | 7.08 M | |||
| Net Asset | 6.3 K |
About GeneThera Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GeneThera's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GeneThera using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GeneThera based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Additional Tools for GeneThera Pink Sheet Analysis
When running GeneThera's price analysis, check to measure GeneThera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneThera is operating at the current time. Most of GeneThera's value examination focuses on studying past and present price action to predict the probability of GeneThera's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneThera's price. Additionally, you may evaluate how the addition of GeneThera to your portfolios can decrease your overall portfolio volatility.